Randomized control study to investigate the effect of rifampicin on prevention of recurrence in patients after radical treatment of primary hepatocellular carcinoma

Trial Profile

Randomized control study to investigate the effect of rifampicin on prevention of recurrence in patients after radical treatment of primary hepatocellular carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Rifampicin (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors GeneCare Research Institute
  • Most Recent Events

    • 19 Apr 2017 Status changed from recruiting to completed.
    • 16 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top